Introduction and objectives: In EDITION 1 (basal + mealtime insulin) and EDITION 2 (basal + OADs), people with T2DM receiving new insulin glargine 300 U/mL (Gla-300) achieved comparable glycaemic control with less hypoglycaemia vs. glargine 100 U/mL (Gla-100).
Methods: This post hoc analysis explored the effect of switching from twice-daily basal insulin to once-daily Gla-300 or Gla-100.
Results: At randomization, 16.9% and 20.0% of people were receiving twice-daily basal insulin in EDITION 1 and EDITION 2, respectively. In these subgroups, glycaemic control was comparable over 6 months in people who switched to Gla-300 or Gla-100 (LS mean difference in HbA1c change from baseline to month 6 −0.01 [95% CI −0.27 to 0.24]% in EDITION 1 and 0.16 [−0.25 to 0.57]% in EDITION 2). As in the overall study cohorts, Gla-300 dose was higher than Gla-100 at month 6 in this analysis. Participants switching from twice- to once-daily basal insulin in EDITION 1 had lower risk of confirmed (≤70 mg/dL [≤3.9 mmol/L]) or severe hypoglycaemia with Gla-300 vs. Gla-100 at night, but not at any time (24 h; possibly influenced by mealtime insulin use), while in EDITION 2, the risk was reduced both at night and at any time (24 h; Table).
Conclusions: As seen overall in EDITION 1 and 2, people with T2DM switching from twice-daily basal insulin to once-daily Gla-300 achieved comparable glycaemic control with less hypoglycaemia vs. those switching to Gla-100.
Supported By: Data previously presented at ADA 75th Scientific Sessions (2015), Boston, MA, USA. Sanofi (NCT01499082, NCT01499095). This analysis was funded by Sanofi. Editorial assistance (Scriptix Pty Ltd) was funded by Sanofi Australia Pty Ltd.